The first clinical trial resulting from a new Zenith Epigenetic collaboration with the National Cancer Institute (NCI) will soon test a combination of the investigational therapy ZEN-3694 plus the immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of resistant ovarian cancer. The new partnership was developed to test ZEN-3694 across several cancer indications. For this upcoming study, the NCI also is collaborating with Bristol Myers Squibb, the developer of Opdivo and Yervoy. “This collaboration will significantly…
You must be logged in to read/download the full post.
The post First Trial in New NCI-Zenith Partnership Will Test ZEN-3694 Combo for Resistant OC appeared first on BioNewsFeeds.